Martin Turner (scientist)
| Martin Turner | |
|---|---|
| Residence | UK |
| Nationality | British |
| Fields | immunology, signal transduction |
| Institutions | Babraham Institute |
Martin Turner (born 03 June 1963) is a molecular biologist, senior group leader at the Babraham Institute, leader of the lymphocyte institute strategic programme. His work helped identify the molecular actors underpinning immune defense, such as tyrosine kinases[1] and microRNAs.[2]
Life
Martin Turner received a BSc in Biochemistry (1985) and a PhD in Immunology (1990) from University College London. He was post-doctoral scientist at the Howard Hughes Medical Institute of the University of Michigan and at the UK National Institute for Medical Research. He joined the Babraham Institute as a principal investigator in 1997 and became head of the laboratory of lymphocyte signalling and development in 2005.
References
- ↑ Martin Turner, P Joseph Mee, Patrick S Costello, Owen Williams, Abigail A Price, Linda P Duddy, Michael T Furlong, Robert L Geahlen, Victor LJ Tybulewicz. Perinatal lethality and blocked B-cell development in mice lacking the tyrosine kinase Syk. Nature 1995, 378: 298-302
- ↑ Antony Rodriguez, Elena Vigorito, Simon Clare, Madhuri V Warren, Philippe Couttet, Dalya R Soond, Stijn van Dongen, Russell J Grocock, Partha P Das, Eric A Miska, David Vetrie, Klaus Okkenhaug, Anton J Enright, Gordon Dougan, Martin Turner, Allan Bradley. Requirement of bic/microRNA-155 for normal immune function. Science 2007, 316: 608-611
External links
This article is issued from Wikipedia - version of the 6/8/2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.